Development and characterization of a novel in vivo model of carcinoid syndrome

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2747-2755

  Jackson, Lindsey N ^a   Chen, L Andy ^a   Larson, Shawn D ^a   Silva, Scott R ^a   Rychahou, Piotr G ^a   Boor, Paulj ^a   Li, Jing ^a   Defreitas, Gilberto ^b   Stafford, W Lane ^a   Townsend, Courtney M ^a   Evers, B Mark ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BEVACIZUMAB; NEUROTENSIN; OCTREOTIDE; SEROTONIN;

ARTICLE; CARCINOID SYNDROME; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HISTOPATHOLOGY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID HEART DISEASE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYINDOLEACETIC ACID; LIVER NEOPLASMS; MALE; MALIGNANT CARCINOID SYNDROME; MICE; MICE, NUDE; OCTREOTIDE; SEROTONIN;

EID: 65249097215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2346     Document Type: Article

References (50)

1. BergeT, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand 1976;84:322-30.
2. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer1961;14:901 -12.
3. Strodel WE, Talpos G, Eckhauser F, Thompson N. Surgical therapy for small-bowel carcinoid tumors. Arch Surg1983;118:391 -7.
4. Calhoun K,Toth-Fejel S,Cheek J, Pommier R.Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003;186:28-31.
5. Roberts LJ, 2nd, Bloomgarden ZT, Marney SR, Jr., Rabin D, Oates JA. Histamine release from a gastric carcinoid: provocation by pentagastrin and inhibition by somatostatin. Gastroenterology 1983;84: 272-5.
6. Evers BM, Ishizuka J, Townsend CM, Jr., Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci 1994;733:393-406.
7. Modlin IM,Kidd M,LatichI,Zikusoka MN,Shapiro MD. Current status ofgastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
8. Thorson A, Biorck G, Bjorkman G, Waldenstrom J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47:795 -817.
9. Evers BM,Townsend CM, Jr., UppJR, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology1991;101:303 -11.
10. Jackson LN, Evers BM. Small bowel carcinoid tumors. 9th ed. Mosby Press; 2007.
11. Woodside KJ, Townsend CM, Jr., Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 2004;8:742 -56.
12. de Vries H, Verschueren R, Willemse P, Kema I, de Vries E. Diagnostic, surgical and medical aspect of the midgut carcinoids. Cancer Treat Rev 2002;28:11 -25.
13. Evers BM, Hurlbut SC, Tyring SK, Townsend CM, Jr., Uchida T, Thompson JC. Novel therapy for the treatment of human carcinoid. Ann Surg 1991;213:411 -6.
14. Lawrence JP, Ishizuka J, Haber B,Townsend CM, Jr., Thompson JC. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. Surgery1990;108:1131 -4; discussion 4-5.
15. Jeng YJ,Townsend CM, Jr., Nagasawa S, et al. Regulation of pancreastatin release from a human pancreatic carcinoid cell line in vitro.Endocrinology 1991;128:220-5.
16. Parekh D, Ishizuka J,Townsend CM, Jr., et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas1994;9:83 -90.
17. Evers BM, Ishizuka J, Townsend CM, Jr., Rajaraman S,Thompson JC. Expression of neurotensin messenger RNA in a human carcinoid tumor. Ann Surg 1991;214:448-54; discussion 54-5.
18. Zhang T,Townsend CM, Jr., Udupi V, et al. Phorbol ester-induced alteration in the pattern ofsecretion and storage of chromogranin A and neurotensin in a human pancreatic carcinoid cell line. Endocrinology 1995;136:2252-61.
19. Townsend CM, Jr., Ishizuka J,Thompson JC. Studies of growth regulation in a neuroendocrine cell line. Acta Oncol 1993;32:125 -30.
20. Ishizuka J, Beauchamp RD, Sato K,Townsend CM, Jr., Thompson JC. Novel action of transforming growth factor β1in functioning human pancreatic carcinoid cells. J Cell Physiol 1993;156:112-8.
21. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 2006;243:833 -42; discussion 43-4.
22. Knuefermann P, Nemoto S, Misra A, et al. CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation 2002;106:2608-15.
23. Nemoto S, De Freitas G, Mann DL, Carabello BA. Effects of changes in left ventricular contractility on indexes of contractility in mice. Am J Physiol Heart Circ Physiol 2002;283:H2504-10.
24. Movat HZ. Demonstration of all connective tissue elements in a single section; pentachrome stains. AMA Arch Pathol 1955;60:289 -95.
25. Garvey W, Fathi A, Bigelow F, Carpenter B, Jimenez C. Improved Movat pentachrome stain. Stain Technol 1986;61:60-2.
26. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3K/Akt pathway. J Am Coll Surg 2007;204: 764-73; discussion 73 -5.
27. SAS/STAT® 9.1 user's guide. In: SAS Institute, editor. Cary (NC): SAS Institute; 2004.
28. Jackson LN, Li J, Chen LA,Townsend CM, Evers BM. over expression of wild-type PKD2leads to increased proliferation and invasion of BON endocrine cells. Biochem Biophys Res Commun 2006;348:945-9.
29. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depotoctreotide with bevacizumab and pegylated interferon α-2b. J Clin Oncol 2008;26:1316-23.
30. Inoue S, Hartman A, Branch CD, et al. mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther 2007;15:287 -94.
31. Salnikov AV, Heldin NE, Stuhr LB, et al. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 2006;119:2795-802.
32. Segerstrom L, Fuchs D, Backman U, Holmquist K, Christofferson R, Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 2006;60:576 -81.
33. Cusack JC, Jr., Liu R, Xia L, et al. NPI-0052enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006;12:6758-64.
34. Musunuru S, Carpenter JE, Sippel RS, Kunnimalaiyaan M, Chen H. A mouse model of carcinoid syndrome and heart disease. J Surg Res 2005;126:102-5.
35. Modlin IM,Tang LH. The gastric enterochromaffin- like cell: an enigmatic cellular link. Gastroenterology 1996;111:783 -810.
36. Kawase S, Ishikura H. Female-predominant occurrence of spontaneous gastric adenocarcinoma in cotton rats. Lab Anim Sci 1995;45:244-8.
37. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroentero- pancreatic system. Ann Oncol 2004;15:966 -73.
38. Souquet JC, Sassolas G, Forichon J, Champetier P, Partensky C, Chayvialle JA. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987;59:1654-60.
39. Ahlman H, Ahlund L, Dahlstrom A, et al. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. Br J Cancer 1987; 56:840-2.
40. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011 -27.
41. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478-86.
42. Marshall JB, Bodnarchuk G. Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol 1993;16: 123-9.
43. Sakai D, Murakami M, Kawazoe K,Tsutsumi Y. Ileal carcinoid tumor complicating carcinoid heart disease and secondary retroperitoneal fibrosis. Pathol Int 2000;50:404-11.
44. Gupta A, Saibil F, Kassim O, McKee J. Retroperitoneal fibrosis caused by carcinoid tumour. Q J Med 1985;56:367-75.
45. Norheim I, Oberg K,Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206:115-25.
46. Boor PJ, Ferrans VJ. Ultrastructural alterations in allylamine cardiovascular toxicity. Late myocardial and vascular lesions. Am J Pathol 1985;121: 39-54.
47. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994;266:L46-52.
48. Reimund E. Methysergide and retroperitoneal fibrosis. Lancet 1987;1:443.
49. Silberstein SD. Methysergide. Cephalalgia 1998;18: 421 -35.
50. Regan JF, Poletti BJ. Vascular adventitial fibrosis in a patient taking methysergide maleate. JAMA 1968; 203:1069-71.